ADRB1 and Vasovagal syncope: Nevertheless, new investigations regarding the efficacy of beta-blockers in the management of vasovagal syncope, as well as the variability in therapeutic responses, have been conducted, and one study has posited that polymorphisms in the beta-1 adrenoceptor result in the activation of receptor signaling and subsequently modify the therapeutic response to beta-blocker therapy [40].